Sumitomo Dainippon Pharma Co., Ltd.

Toray Industries, Inc.

International Institute of Cancer Immunology, Inc.

Sumitomo Pharma Co., Ltd.

Yukihiro Nishio

Hitoshi Ban

Masashi Goto

Yosuke Takanashi

Chiang Jia Li

Toshio Nishihara

Hiroyuki Meguro

Mie Kaino

Tomohide Masuda

Keiichi Okimura

Yuko Kubota

Hideyuki Tsutsui

Syuji Udagawa

Yumiko Sekiya

Masashi Yamamoto

Atsushi Suwa

Shinya Yokosaka

Padma Malyala

Bilikallahalli K Muralidhara

Yutaka Nishimura

Marcus Wong

A compound represented by formula (1): wherein

Hemiasterlin derivatives and antibody-drug conjugates including same

A compound represented by the formula (1): wherein Xand Yare each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, Ris a hydrogen atom, a group represented by the formula (2): wherein Xand Yare each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

WT1 antigen peptide conjugate vaccine

A peptide derivative represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents an oxygen atom or NR, Y represents NH, N(Me)H, SH, OH, or phenyl in which any one of hydrogen atoms is replaced by NHor OH, and R represents a hydrogen atom or C-Calkyl, provided that the derivative where X is NH, and Y is NH, and the derivative where X is NH, and Y is N(Me)H are excluded.

Peptide derivative and use thereof

The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L, L, X, R, R, R, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts. 

Adenine conjugate compounds and their use as vaccine adjuvants

The present invention provides a compound represented by the formula (1): wherein Xand Yare each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, andRis a hydrogen atom; a group represented by the formula (2): wherein Xand Yare each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xand Yare each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue,or a salt thereof, for example.

Conjugate vaccine using trimming function of ERAP1

A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof. 

Urea derivative and use therefor

A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, Ris trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each Ris independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; Ris a hydrogen atom, halogen atom, C-Calkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or RO&#x2014;; and Ris phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R.

Growing community of inventors

Osaka, Japan

Yukihiro Nishio